Evidence map›Paper›PMID 36876272›Full record

ArticleProceedings (Baylor University. Medical Center)2023

Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients.

Azizullah Beran, Asmaa Mhanna, Mohammed Mhanna, Ramzi Hassouneh, Ziad Abuhelwa, Mouhand F H Mohamed, Wasef Sayeh, Rami Musallam, Ragheb Assaly, Khaled Abdeljawad

Open access · greenAbstract read
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Azizullah BeranDivision of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana.ORCID https://orcid.org/0000-0002-4161-942X
Asmaa MhannaDepartment of Pediatrics, ProMedica Hospital, Toledo, Ohio.
Mohammed MhannaDivision of Cardiology, University of Iowa, Iowa City, Iowa.
Ramzi HassounehDivision of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana.
Ziad AbuhelwaDepartment of Internal Medicine, University of Toledo, Toledo, Ohio.
Mouhand F H MohamedDepartment of Internal Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
Wasef SayehDepartment of Internal Medicine, University of Toledo, Toledo, Ohio.
Rami MusallamDepartment of Internal Medicine, St. Vincent Charity Medical Center, Cleveland, Ohio.
Ragheb AssalyDepartment of Internal Medicine, University of Toledo, Toledo, Ohio.
Khaled AbdeljawadDivision of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana.
Indiana University – Purdue University Indianapolis · USUniversity of Toledo · USBrown University · USProMedica Toledo Hospital · USSt. Vincent Charity Hospital · USUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 vaccinations were found to be highly effective in phase 3 clinical trials. However, these trials have not reported data regarding the subgroup of liver disease or excluded patients with liver disease. The effectiveness of COVID-19 vaccines among liver cirrhosis (LC) patients is unclear. We conducted this meta-analysis to assess the effectiveness of SARS-CoV-2 vaccination in LC patients. A comprehensive literature search was conducted to include all the relevant studies that compared the outcomes of LC patients who received SARS-CoV-2 vaccines vs. unvaccinated patients. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by the Mantel-Haenszel method within a random-effect model. Four studies with 51,834 LC patients (20,689 patients received at least one dose vs 31,145 were unvaccinated) were included. COVID-19-related complications, including hospitalization (RR 0.73, 95% CI 0.59-0.91,

Indexed as

Chronic liver diseaseCOVID-19 vaccineliver cirrhosisSARS-CoV-2 vaccine

Identifiers

PMID36876272
PMCPMC9980592
OpenAlexW4319834396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.